Compass Therapeutics, Inc. (CMPX)

Market Cap	956.27M +199.4%
Revenue (ttm)	n/a
Net Income	-66.49M
EPS	-0.42
Shares Out	180.09M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,624,354
Open	5.45
Previous Close	5.49
Day's Range	5.20 - 5.53
52-Week Range	1.40 - 6.88
Beta	1.30
Analysts	Strong Buy
Price Target	15.83 (+198.12%)
Earnings Date	May 7, 2026

About CMPX

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company’s lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; C...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 39
• Stock Exchange: NASDAQ
• Ticker Symbol: CMPX
• Website: https://www.compasstherapeutics.com

Analyst Summary

According to 8 analysts, the average rating for CMPX stock is "Strong Buy." The 12-month stock price target is $15.83, which is an increase of 198.12% from the latest price.

Price Target

$15.83

(198.12% upside)

Analyst Consensus: Strong Buy